SELLAS Life Sciences surged in pre-market trade after its Phase 2 trial of SLS009 in relapsed or refractory AML showed encouraging results. The SLS009-AZA-VEN combo delivered a 46% overall response rate, rising to 58% in patients with only one prior treatment line, driving strong retail interest in the stock.